Compare NUV & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NUV | KARD |
|---|---|---|
| Founded | 1987 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2026 |
| Metric | NUV | KARD |
|---|---|---|
| Price | $8.08 | $11.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | ★ 1.3M | 441.3K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.02 | $12.23 |
| 52 Week High | $9.26 | $27.00 |
| Indicator | NUV | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 35.74 |
| Support Level | $8.05 | N/A |
| Resistance Level | $8.34 | $16.26 |
| Average True Range (ATR) | 0.09 | 1.30 |
| MACD | -0.03 | -0.24 |
| Stochastic Oscillator | 7.14 | 0.60 |
Nuveen Municipal Value Fund Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.